Daewon Pharmaceutical said Tuesday that it has signed a licensing agreement with Tium Bio for the latter’s TU2670, endometriosis and uterine leiomyoma drug candidate.
TU2670 is a next-generation oral drug candidate that reduces estrogen secretion by inhibiting the gonadotropin-releasing hormone (GnRH) receptor. The drug improved the convenience of taking the medication compared to existing therapeutic agents, which are mainly injectable formulations.
Tium has completed phase 1 clinical trial of the drug and plans to commercialize the product in 2025 after completing the remaining tests.
With the transfer, Daewon will take charge of all development, production, and commercialization of the product in Korea.
Endometriosis is a disease in which endometrial tissue attaches to other organs other than the uterus. The condition affects about 10 percent of Koreans, while typical symptoms include pelvic pain that occurs during menstrual periods, which can cause infertility.
Uterine leiomyoma is a disease caused by the abnormal proliferation of uterine smooth muscle. Typical symptom includes excessive menstruation.
“The global endometriosis treatment market is steadily growing and is expected to exceed $3 billion by 2027,” a company official said. “After launching the product, the company plans to expand coverage by adding indications such as gonadal sterility, and actively promote exports.”
<© Korea Biomedical Review, All rights reserved.>